WEALTH Published 2024 · Summer 6 min readUpdated 2026-09-22

The trillion-dollar signal

The molecule makers got rich first. The practice economy is next.

Written by Brookes Bruno · Founder, PrimeBodyRX

The trillion-dollar signal

Eli Lilly became the first pharmaceutical company in history to cross $1 trillion in market value, powered by GLP-1 drugs. Wall Street's answer was fast: J.P. Morgan projected the incretin market at $200 billion by 2030.

What happened

A single therapeutic class carried a drugmaker past a trillion dollars in market value, and research desks re-forecast the category upward within the same season.

Capital, in other words, stopped treating this as a fad and started treating it as infrastructure.

What it means in practice

The best practice the field took from 2024: when capital moves at that size, the services layer around it — prescribing, fulfillment, financing — is where practices capture durable value.

The molecule makers got rich first. The practice economy is next.

Sources
Written by

Brookes Bruno

Founder, PrimeBodyRX

The Daily Demo

See the platform behind the reporting.

The Daily Demo walks the sourcing, prescriber review and financing these pages document. Tell us where to reach you.